Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry

被引:49
|
作者
Clarke, Lorne A. [1 ]
Giugliani, Roberto [2 ]
Guffon, Nathalie [3 ]
Jones, Simon A. [4 ]
Keenan, Hillary A. [5 ]
Munoz-Rojas, Maria, V [5 ]
Okuyama, Torayuki [6 ]
Viskochil, David [7 ]
Whitley, Chester B. [8 ,9 ]
Wijburg, Frits A. [10 ]
Muenzer, Joseph [11 ]
机构
[1] Univ British Columbia, BC Childrens Hosp Res Inst, Dept Med Genet, Vancouver, BC, Canada
[2] Fed Univ Rio Grande & Med Genet Serv, Dept Genet, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[3] Hop Femme Mere Enfant, Ctr Reference Malad Hereditaires Metab, Bron, France
[4] Manchester Univ NHS Trust, Manchester Ctr Genom Med, Manchester, Lancs, England
[5] Sanofi Genzyme, Cambridge, MA USA
[6] Natl Ctr Child Hlth & Dev, Dept Clin Lab Med, Tokyo, Japan
[7] Univ Utah, Salt Lake City, UT USA
[8] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA
[9] Univ Minnesota, Expt & Clin Pharmacol, Minneapolis, MN USA
[10] Acad Med Ctr, Dept Pediat, Amsterdam, Netherlands
[11] Univ N Carolina, Chapel Hill, NC 27515 USA
关键词
genotype-phenotype; hurler syndrome; iduronidase; lysosomal storage disease; lysosome; metabolic disease; mucopolysaccharidosis; Scheie syndrome; ALPHA-L-IDURONIDASE; IDENTIFICATION; DIAGNOSIS;
D O I
10.1111/cge.13583
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disorder resulting from pathogenic variants in the alpha-L-iduronidase (IDUA) gene. Clinical phenotypes range from severe (Hurler syndrome) to attenuated (Hurler-Scheie and Scheie syndromes) and vary in age of onset, severity, and rate of progression. Defining the phenotype at diagnosis is essential for disease management. To date, no systematic analysis of genotype-phenotype correlation in large MPS I cohorts have been performed. Understanding genotype-phenotype is critical now that newborn screening for MPS I is being implemented. Data from 538 patients from the MPS I Registry (380 severe, 158 attenuated) who had 2 IDUA alleles identified were examined. In the 1076 alleles identified, 148 pathogenic variants were reported; of those, 75 were unique. Of the 538 genotypes, 147 (27%) were unique; 40% of patients with attenuated and 22% of patients with severe MPS I had unique genotypes. About 67.6% of severe patients had genotypes where both variants identified are predicted to severely disrupt protein/gene function and 96.1% of attenuated patients had at least one missense or intronic variant. This dataset illustrates a close genotype/phenotype correlation in MPS I but the presence of unique IDUA missense variants remains a challenge for disease prediction.
引用
收藏
页码:281 / 289
页数:9
相关论文
共 50 条
  • [1] REVIEW OF 16 PATIENTS WITH THE ATTENUATED MUCOPOLYSACCHARIDOSIS TYPE I (MPS I) PHENOTYPE
    Guffon, N.
    Bourlon-Forest, I
    Froissart, R.
    Maire, I
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 181 - 181
  • [2] Characterization of Surgical Procedures in Patients with Mucopolysaccharidosis Type I: Findings from the MPS I Registry
    Arn, Pamela
    Wraith, J. Edmond
    Underhill, Lisa
    JOURNAL OF PEDIATRICS, 2009, 154 (06): : 859 - 864
  • [3] Genotype frequencies in the MPS I Registry
    Cox, Gerald F.
    Wraith, J. Edmond
    Whitley, Chester
    Wijburg, Frits A.
    Guffon, Nathalie
    MOLECULAR GENETICS AND METABOLISM, 2009, 96 (02) : S19 - S19
  • [4] GLYCOSAMINOGLYCANS AS ANTICOAGULANTS IN MUCOPOLYSACCHARIDOSIS TYPE I (MPS I)
    Tolar, J.
    Orchard, P. J.
    Key, N.
    Blazar, B. R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 46 - 46
  • [5] Glycosaminoglycans as anticoagulants in mucopolysaccharidosis type I (MPS I)
    Tolar, Jakub
    Orchard, Paul J.
    Key, Nigel
    Blazar, Bruce R.
    BLOOD, 2007, 110 (11) : 55B - 55B
  • [6] Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
    Kristin D’Aco
    Lisa Underhill
    Lakshmi Rangachari
    Pamela Arn
    Gerald F. Cox
    Roberto Giugliani
    Torayuki Okuyama
    Frits Wijburg
    Paige Kaplan
    European Journal of Pediatrics, 2012, 171 : 911 - 919
  • [7] Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
    D'Aco, Kristin
    Underhill, Lisa
    Rangachari, Lakshmi
    Arn, Pamela
    Cox, Gerald F.
    Giugliani, Roberto
    Okuyama, Torayuki
    Wijburg, Frits
    Kaplan, Paige
    EUROPEAN JOURNAL OF PEDIATRICS, 2012, 171 (06) : 911 - 919
  • [8] Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry
    Viskochil, David
    Clarke, Lorne A.
    Bay, Luisa
    Keenan, Hillary
    Muenzer, Joseph
    Guffon, Nathalie
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2019, 179 (12) : 2425 - 2432
  • [9] Treatment trends in MPS I: The MPS I registry
    Guffon, N.
    Clarke, J.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 106 - 106
  • [10] Neurodevelopmental outcomes in patients with mucopolysaccharidosis type I (MPS I)
    Jeyakumar, Yaanu
    Piercy, Jamie
    Manak, Eva
    Inbar-Feigenberg, Michal
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S80 - S81